We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31Á4%) and thrombocytopenia (6Á8%). The overall response rate (ORR) by investigator-based assessment was 85Á4%. Most patients (74%) underwent successful central laboratorybased molecular cytogenetic analysis. No clinically relevant differences in ORR post-induction were seen between patients with or without high-risk cytogenetic abnormalities (86Á2% vs. 84Á3%). Further follow-up data are available for 113 patients receiving ASCT who were included in a prospective consolidation trial (median follow-up, 55Á5 months); median progression-free survival (PFS) was 35Á3 months and median overall survival (OS) was not reached. In patients with high-risk versus standard-risk cytogenetics, median PFS was 19Á9 vs. 43Á6 months (P < 0Á0001), and median OS was 54Á7 months versus not reached (P = 0Á0022). VCD is an effective and tolerable induction regimen; results suggest that VCD induces high response rates independently of cytogenetic risk status, but after long-term follow-up, cytogenetic high risk is associated with markedly reduced PFS and OS post-ASCT.
High-dose therapy plus autologous stem-cell transplantation (HDT/ASCT) is the standard of care for younger, previously untreated multiple myeloma (MM) patients, commonly defined as those aged ≤65 years or medically fit patients aged up to 70-75 years (Cavo et al, 2011; Moreau et al, 2011a; Anderson et al, 2015) . Vincristine, doxorubicin and dexamethasone has traditionally been a standard induction therapy prior to ASCT, but the complete response (CR) rate is only 2-8%, and that of at least very good partial response (≥VGPR) only 7-18% (Cavo et al, 2011; Moreau et al, 2011a) .
In MM, increased depth of response after induction and HDT/ASCT is associated with improved outcomes. Achievement of CR, or ≥VGPR, now represents a major endpoint for strategies incorporating ASCT into first-line treatment (Attal et al, 1996; van de Velde et al, 2007; Chanan-Khan & Giralt, 2010; Kobayashi et al, 2013) . More recently, the achievement of minimal residual disease-negative status, defined as molecular or immunophenotypic CR in the latest International Myeloma Working Group (IMWG) response criteria (Rajkumar et al, 2011) , has been associated with significantly improved progression-free survival (PFS) (Korthals et al, 2012; Rawstron et al, 2013) . The novel agents thalidomide, bortezomib and lenalidomide have greatly advanced MM treatment during the past decade (Richardson et al, 2007; Cavo et al, 2011) ; these agents have been incorporated into induction treatments to increase rates of response (≥VGPR) before ASCT and thereby improve outcomes posttransplantation (Attal et al, 2007; Cavo et al, 2010; Harousseau et al, 2010) .
We, and others, have shown that bortezomib, cyclophosphamide and dexamethasone (VCD) is an effective regimen in relapsed/refractory MM and is associated with an acceptable tolerability profile (Davies et al, 2007; Kropff et al, 2007; Ahn et al, 2012; Fu et al, 2012) . Several small studies have suggested VCD may also be an effective induction treatment for previously untreated MM (Bensinger et al, 2010; Reeder et al, 2010; Kumar et al, 2012) , and a recent study compared VCD with bortezomib-doxorubicin-dexamethasone (PAD) as induction therapy in previously untreated MM (Mai et al, 2015) . The multicentre study presented here aimed to assess the efficacy and safety of VCD as induction therapy in a large cohort of patients with previously untreated MM. The previously reported first part of the study determined the maximum tolerated dose of cyclophosphamide to be 900 mg/m 2 (Kropff et al, 2009) . Here, we report results of the second part of the study, which assessed efficacy and tolerability, and included a comprehensive, centralised molecular cytogenetic analysis of patients, as well as data on the post-transplant course in a subgroup of patients.
Patients and methods

Patients
Patients aged 18-60 years with previously untreated MM (Durie-Salmon stage II/III), adequate haematological function (leucocytes ≥3Á0 9 10 9 /l, neutrophils ≥3Á0 9 10 9 /l), creatinine clearance >30 ml/min, Karnofsky performance status ≥60% and aspartate aminotransferase or alanine aminotransferase <2Á5 times the upper limit of normal (ULN) were eligible for enrolment. Patients were also required to fulfil one or more 'CRAB' criteria: hypercalcaemia (serum level >0Á25 mmol/l [1 mg/dl] over ULN or >2Á5 mmol/l [10 mg/ dl]); impaired renal function (serum creatinine >173 lmol/l [2 mg/dl]); anaemia (haemoglobin 20 g/l below the lower limit of normal or <10 g/l); or bone alterations (lytic lesions or osteoporosis with compression bone fractures). Patients with grade ≥2 peripheral neuropathy, or other serious concomitant diseases determined by the investigator to be in conflict with study participation, were excluded. Review boards at all participating institutions approved the study, which was conducted according to the provisions of the Declaration of Helsinki, International Conference on Harmonisation, and Guidelines for Good Clinical Practice. Patients provided written informed consent. Prophylaxis for herpes zoster, cystitis and peptic ulcers was recommended, but not mandatory. The primary study endpoint was to evaluate the efficacy of VCD induction [overall response rate (ORR); CR + partial response (PR) combined, according to the relevant European Society for Blood and Marrow Transplantation (EBMT) criteria] current at study termination (Blad e et al, 1998) . Secondary objectives included assessment of tolerability and of response according to baseline cytogenetic alterations.
Study design
Following three cycles of VCD induction, patients were offered stem-cell collection and high-dose melphalan in combination with ASCT as per local good clinical practice.
Outside this clinical trial, patients were then eligible for participation in a randomised treatment study of bortezomib as consolidation therapy following HDT/SCT (DSMM XIb; MMY3012/MMY3013). Only patients who subsequently enrolled in the MMY3012/MMY3013 consolidation trial were prospectively monitored and externally audited after ASCT and analysed for ORR, long-term PFS and OS. The majority of patients who received VCD induction, but did not enrol in MMY3012/MMY3013, may have also received high dose chemotherapy and ASCT but were not followed up, monitored or externally audited after ASCT and could not, therefore, be included in this analysis.
Assessments
Response rates (CR + PR) were determined by investigators according to EBMT criteria (Blad e et al, 1998) . To accommodate the updated criteria for response assessment, as developed by the IMWG, the protocol was amended to include assessment of response by an external expert as a secondary endpoint, including the category of VGPR (Durie et al, 2006) . Molecular cytogenetic analysis was performed by a centralised reference laboratory using fluorescence in situ hybridisation (FISH). Adverse events (AEs) were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_appli cations/docs/ctcaev3.pdf). While the protocol did not include post-HDT/ASCT assessment, the majority of patients received subsequent therapy. One hundred and thirteen patients from this trial subsequently entered a prospective study of post-transplant consolidation therapy with bortezomib: MMY3012/MMY3013 (NCT00416273) in which the post-transplant course was monitored prospectively and externally audited. Therefore only data on post-HDT/ASCT response, PFS and OS for these patients were available and were reported in this analysis.
Statistical analyses
The safety population included all patients who received bortezomib at least once, independently of accordance with the protocol; patients from the first part of the study (where optimal cyclophosphamide dose was determined through titration) were only included in the safety population if their cyclophosphamide dose did not fall below or rise above the dose established for the second part of the study (i.e. 900 mg/m 2 body surface area) by a factor of 0Á5 (acceptable range, 450-1350 mg/m 2 ). The response-evaluable population comprised patients who received ≥1 complete cycle of bortezomib (four doses per cycle) with an investigator-based response assessment at the end-of-study visit; patients from the first part of the study were only included if the cyclophosphamide dose they received did not increase or decrease above or below 900 mg/m 2 by a factor of 0Á2 (acceptable range, 720-1080 mg/m 2 ). As previous studies have suggested a dose-response relationship for cyclophosphamide (Davies et al, 2007; Ahn et al, 2012) , a lower cut-off limit was used for the response-evaluable population to avoid inclusion of patients with clinically relevant differences in cyclophosphamide dosing. A response rate ≥72Á5% was expected with VCD induction. An exact binomial test with a nominal 0Á05 two-sided significance level had 80% power to detect the difference between the null hypothesis proportion (p 0 ) of 0Á66, and the alternative proportion (p A ) of 0Á725, when the sample size was defined with 400 patients. The chi-square test for contingency 
Results
Patients
Overall, 414 patients with previously untreated MM were enrolled between 17 March 2006 and 5 June 2009 at 41 study centres in Germany. Of these, 399 received ≥1 dose of bortezomib ( Fig 1) ; four patients from the first part of the study were not included in the present analysis as they had received >1350 mg/m 2 cyclophosphamide (>150% of the maximum tolerated dose), leaving 395 patients in the safety population. Baseline characteristics of these 395 patients are shown in Table I . Mean [AE standard deviation (SD)] time between first diagnosis of MM and screening was 7Á5 AE 23Á2 months (median, 1Á0 months). As permitted by the inclusion criteria, five patients classified as Durie-Salmon stage I were included in the trial.
Efficacy
The response-evaluable population included 391 patients who received ≥1 complete cycle of bortezomib and had an investigator-based response assessment at end-of-study visit.
The investigator-based ORR [≥PR; EBMT criteria (Blad e et al, 1998)] post-induction and prior to stem-cell mobilisation was 85Á4% (Table II) . Mean (AESD) time to best response was 62Á6 AE 16Á3 days (n = 353). Among 288 patients who were evaluable for this assessment, expert-based ORR [≥PR; IMWG criteria (Durie et al, 2006) ] post-induction and prior to stem-cell mobilisation was 86Á2%, including 4Á5% CR (n = 15), 4Á2% unconfirmed CR (n = 14), 31Á7% VGPR (n = 106) and 45Á8% PR (n = 153).
Efficacy in patients with cytogenetic abnormalities
A total of 291 (74%) patients had successful molecular cytogenetic analysis by FISH (sample not taken, n = 53; sample not analysed, n = 15; analysis unclassifiable, n = 32); of these, 102 did not have abnormalities and 189 patients had cytogenetic abnormalities (Table I ). The most common aberration was del(13q) (n = 112), 38 patients had t(4;14) and 31 had del(17p); 104 patients had other chromosomal abnormalities (not specified). Cytogenetic abnormalities associated with poor risk at the time of study were specified, other cytogenetic abnormalities were not further listed separately.
There were no clinically relevant differences in ORR between patients with and those without cytogenetic abnormalities (86Á2% vs. 84Á3%, respectively). In a subgroup analysis of the response-evaluable population, the ORR was highest in patients with del(13q) (101/112; 90Á2%) and lowest in patients with del(17p) (23/31; 74Á2%) (Table III) . A high proportion of patients (34/38; 89Á5%) with t(4;14) responded to VCD induction.
Analysis of factors predictive of response
Based on the dichotomised response [response versus no response; EBMT criteria (Blad e et al, 1998)], univariate analysis using chi-square testing found that b 2 -microglobulin level (<3Á5 vs. ≥3Á5 and <5Á5 vs. ≥5Á5 mg/l), presence of newonset treatment-emergent polyneuropathy, and severity of treatment-emergent polyneuropathy were predictive of response (P < 0Á05) (Table IV) . Within a sensitivity analysis using a multivariate logistic regression model ß 2 -microglobulin level remained a significant predictor.
Post-transplant response and long-term outcomes
Of the 414 patients who underwent VCD induction, 113 (27Á3%) successfully completed subsequent stem cell collection, were free from progressive disease after high-dose melphalan/ASCT and provided informed consent for subsequent enrolment into MMY3012 (DSMM XIb). Only these patients were monitored further. Thus despite the majority of patients having sufficient stem cell mobilization following HDT/ ASCT, only those patients who agreed to participate in the consecutive trial were analysed for post-ASCT response and PFS/OS. Among 112 response-evaluable patients, the post-HDT/ASCT ORR (i.e. prior to any consolidation therapy) was 95Á5%, including 30Á4% CR, with a ≥VGPR rate of 67Á0% (Table II) . At a median follow-up of 55Á5 months (range, 2Á6-75Á7), median PFS was 35Á3 months [95% confidence interval (CI): 27Á8-45Á9] and median OS (as measured from the start of MM treatment i.e. first dose of the induction therapy) was not yet reached.
Among 112 evaluable patients included in the post-transplant assessment, 89 underwent successful cytogenetic analysis; of these, 49 had cytogenetic aberrations, which included del(13q) (n = 23), t(4;14) (n = 10), del(17p) (n = 5) and 1q gain (n = 5). Subsequent assessments for abnormalities in cytogenetics during the study were not performed. Post-HDT/ASCT response rates [IMWG criteria (Durie et al, 2006) ] were similar in patients with high-risk cytogenetic abnormalities (del 17p, t(4;14), 1q gain; n = 18), other cytogenetic abnormalities (n = 35) and no abnormalities (n = 36), as shown in Table III . Kaplan-Meier curves of PFS and OS in patients with high-risk, other and no cytogenetic abnormalities are shown in Fig 2. Median PFS was shorter in patients with high-risk cytogenetic abnormalities (19Á9 months, 95% CI: 15Á9-27Á6) than in patients with cytogenetic abnormalities with no negative predictive value (48Á3 months, 95% CI: 31Á5-not estimable; P < 0Á0001) or no cytogenetic abnormalities (43Á6 months, 95% CI: 38Á0-68Á4; P < 0Á0001), respectively. Similarly, median OS was 54Á7 months (95% CI: 38Á0-68Á4) for the high-risk group and not reached for patients with cytogenetic abnormalities with no negative predictive value (P = 0Á0022) or no cytogenetic abnormalities (P = 0Á0002).
Treatment exposure and safety
In total, 89Á4% of patients (n = 353) completed three cycles of VCD induction. Premature termination was due to: AE (n = 24), protocol violation (n = 7), progression of MM (n = 4), death (n = 2), worsening of comorbidity (n = 1), withdrawal of informed consent (n = 1) or other reasons (n = 11) (patients could report multiple reasons for premature termination). For cycles 1, 2 and 3 respectively, the percentage of planned doses received for bortezomib was 99Á6%, 99Á7% and 99Á4%; for cyclophosphamide 100Á1%, 98Á6% and 98Á4%; and for dexamethasone 99Á4%, 98Á6% and 97Á9%. Among patients with (n = 154)/without (n = 241) polyneuropathy, the percentage of planned bortezomib doses received during cycles 1, 2 and 3 was 100Á0%/99Á3%, 99Á8%/ 99Á6% and 100Á0%/98Á9%, respectively. Overall, dose reductions due to AEs (in least one of the 3 study drugs) were required in 9Á1% of patients, with 26Á6% of patients requiring a temporary stop in therapy. Reductions in the dose of either bortezomib, cyclophosphamide or dexamethasone due to AEs were required in 6Á6%, 3Á3% and 0Á5% of patients, respectively.
Treatment-emergent AEs occurred in 392 patients (99Á2%); grade ≥3 AEs occurred in 214 patients (54Á2%). The most common AEs were leucopenia (53Á4%, 31Á4% grade ≥3) and thrombocytopenia (32Á7%, 6Á9% grade ≥3) ( Table V) . Treatment-emergent serious AEs (SAEs) occurred in 103 patients (26Á1%), most commonly pneumonia (3Á8%), pyrexia (3Á5%) and leucopenia (2Á8%); 88Á6% of all SAEs resulted in hospitalisation or prolonged hospitalisation. SAEs leading to treatment discontinuation in 21 patients included pneumonia (n = 3), and herpes zoster, sepsis, leucopenia, neutropenia, vomiting and cardiac failure (each n = 2).
Any-grade AEs related to herpes zoster infection were reported in 32 patients (8Á1%), including grade 3 in seven patients (1Á8%); there were no grade 4 events. Only one case of herpes zoster infection (grade 1) occurred in patients taking acyclovir prophylaxis (n = 95). Overall, 154 patients (39Á0%) had an AE relating to polyneuropathy, including paraesthesia (n = 63, 15Á9%), polyneuropathy (n = 54, 13Á7%), hypoesthesia (n = 27, 6Á8%), dysgeusia (n = 20, 5Á1%), neuralgia (n = 8, 2Á0%), neuropathy (n = 4, 1Á0%), peripheral neuropathy (n = 4, 1Á0%) and peripheral sensory neuropathy (n = 4, 1Á0%). Eleven patients (2Á8%) had grade 3 polyneuropathy-related AEs. Polyneuropathy-related AEs resolved without sequelae in 116/154 (75%) patients: mean (AESD) time to resolution in these patients was 28Á6 (AE50Á9 days) (median: 17Á5 days). Six patients (1Á3%) died during the induction treatment with VCD. Two of the deaths were considered not related to bortezomib: one case of disease progression was considered unrelated to any component of VCD induction, and one case of gastric haemorrhage was considered not related to bortezomib or cyclophosphamide but possibly related to dexamethasone. Two cases of acute cardiac failure were considered as possibly related to the study regimen (bortezomib and/or cyclophosphamide), and one case of septic shock with pneumonia and respiratory failure was probably related to bortezomib and cyclophosphamide, and possibly related to dexamethasone. No transplant-related mortality was reported in the 113 patients undergoing ASCT and consolidation.
Discussion
At the time of study initiation, bortezomib was not typically used as first-line therapy; our study, therefore, aimed to assess a bortezomib-containing triple induction regimen in previously-untreated patients with MM, including those with different risk profiles. Induction chemotherapy followed by HDT/ASCT is now the therapy of choice in transplant-eligible MM (Moreau et al, 2011a) . Here, we demonstrated a high ORR rate (85Á4%) with three cycles of VCD induction. This is comparable with reports for other bortezomib-containing induction regimens, including bortezomib-dexamethasone (VD), bortezomib-thalidomide-dexamethasone (VTD), bortezomib-lenalidomide-dexamethasone (VRD) and PAD (ORR rates of 78-100%) (Cavo et al, 2010; Harousseau et al, 2010; Richardson et al, 2010; Sonneveld et al, 2012; Goldschmidt et al, 2013; Ludwig et al, 2013) . As seen with other triplet regimens including VTD and VRD (Cavo et al, 2010; Roussel et al, 2014) , depth of response with VCD was further improved post-HDT/ASCT (ORR 95Á5%; ≥VGPR 67Á0%). A recent study showed that induction with VTD versus VCD achieved ORRs of 92% and 83%, respectively, with ≥VGPR rates of 66% and 56% . The response rates presented here confirm the utility of VCD as an effective induction regimen for transplant-eligible MM.
Incorporation of two novel agents in a single induction regimen may further increase response rates when compared with those containing a single novel agent. High response rates have been reported with VTD (ORR 93-100%, ≥VGPR 62-69%) (Cavo et al, 2010; Ludwig et al, 2013) and VRD (ORR 100%, ≥VGPR 67%) (Richardson et al, 2010) . However, it is unknown whether such response rates translate into improved long-term outcomes following HDT/ASCT. Indeed, a recent retrospective comparison of VCD and VRD induction reported comparable outcomes in terms of response, PFS and OS (Kumar et al, 2013) , indicating that the substantially increased costs associated with combining two novel agents in the VRD regimen may not be justified in terms of outcome benefit versus the VCD regimen. Further analysis showed that, in terms of cost efficacy and health resource utilisation, VCD is preferable to VRD for induction (Kumar et al, 2016) .
Many myeloma cells carry cytogenetic aberrations, such as del(13q), del(17p) and t(4;14) (Sonneveld et al, 2016) , which have been associated with unfavourable long-term outcomes (Neben et al, 2010; Avet-Loiseau et al, 2012) . Bortezomibbased therapies have previously been shown to induce high response rates in patients with high-risk cytogenetic abnormalities (Cavo et al, 2010; Harousseau et al, 2010; Sonneveld et al, 2012) . In our study, which utilised a centralised reference laboratory, there were no meaningful differences in ORR among cytogenetic subgroups, and patients with/without cytogenetic aberrations achieved a similarly high ORR (86Á2%/84Á3%). Furthermore, del(13q), t(4;14) and del(17p) were not predictive for reduced response to VCD induction, despite a lower ORR in del(17p) patients (74Á2%) compared with the overall population (85Á4%). Of these three abnormalities, del(17p) and t(4;14) are consistently associated with a poor prognosis, while loss of 13q by FISH is believed to have more variable prognostic significance (Nahi et al, 2011; Sawyer, 2011; Kalff & Spencer, 2012) . In agreement with some previous studies (Paiva et al, 2012; Rosinol et al, 2012), patients with high-risk cytogenetic abnormalities had poorer PFS and OS following HDT/ASCT than those without such abnormalities, despite showing similar rates and quality of response. This suggests that poor prognosis cannot be overcome fully by short-term induction with a bortezomibcontaining regimen. There was no significant difference in ORR or response quality after induction therapy when comparing high-and standard-risk patients. VCD induction seemed to overcome high-risk cytogenetic features. More rapid progression in these high-risk patients supports consolidation and maintenance with proteasome inhibitors as reported in the Hemato-Oncology Cooperative Group/German Multicentre Myeloma Group (HOVON/GMMG) study . High-risk patients who fail bortezomib-based induction and HDT/ASCT may benefit from newer regimens combining lenalidomide-dexamethasone with novel proteasome inhibitors (ixazomib or carfilzomib) or targeted antibodies (daratumumab or elotuzumab), which may abrogate some of the negative effects of high-risk cytogenetics on outcomes (Sonneveld et al, 2016) .
Risk factor analysis identified the presence and increased severity of new-onset polyneuropathy (predominantly grade 1/2 AEs) as predictors of response (P = 0Á0025 and P = 0Á0137, respectively). This contrasts with data from the VISTA (Velcade â as Initial Standard Therapy in Multiple Myeloma) study where there was no correlation between the occurrence of peripheral neuropathy and ORR or time to progression on multivariate analysis in newly diagnosed, transplant-ineligible patients receiving bortezomib-melphalan-prednisone . Although the present study probably comprises the largest uniformly treated patient population who received bortezomib-containing induction, further analysis is needed to explain fully the correlation between the incidence/severity of peripheral neuropathy and quality of response. Explanations may include a higher cumulative bortezomib dose received, increased sensitivity of neurones and MM cells, and genetic predisposition for higher response/neurotoxicity to proteasome inhibitors (Broyl et al, 2010; Du et al, 2011; Favis et al, 2011) . VCD has an acceptable tolerability profile, as highlighted in a recent direct comparison with PAD (Goldschmidt et al, 2013) . Here too, VCD was generally well tolerated and, consistent with the known safety profile of bortezomib (Kouroukis et al, 2014) , the most common AEs included leucopenia and thrombocytopenia. In our study, the rate of severe infections was particularly low; only 1Á8% of patients had grade 3 herpes-related infections, with no grade 4 events. The pattern Table III . ORRs in cytogenetic subgroups after VCD induction therapy and after HDT/ASCT. After VCD induction † Response, % Two-sided P-value,* testing ORR = 66% ORR (≥PR) All response-evaluable patients (n = 391)
After HDT/ASCT ¶ ORR (≥PR)/≥VGPR (Durie et al, 2006) . **Defined as deletion 17p, t(4;14), gain 1q. † †Other cytogenetic abnormalities included monosomies 4, 11, 13, 14 and 16; trisomies 3, 4, 5, 9, 11, 13, 15, 17 and 21; tetrasomies 5, 9, 11 and 15; deletions 11q, 13q, 14q and 22q ; gains 9q and 17q; rearrangement/deletion at immunoglobulin heavy (IGH) locus; and translocations t(2;8) and t(11;14). For these chromosomal aberrations, no prognostic information exists.
of herpes-related infections strongly emphasises the benefit of acyclovir prophylaxis for preventing and attenuating these AEs, as all but one herpes-related infection (grade 1) was seen in patients who did not receive prophylaxis.
Treatment-emergent polyneuropathy is an important complication of MM and a notable toxicity of bortezomib (Argyriou et al, 2008; Richardson et al, 2012) . Overall, 39% of patients had an AE relating to polyneuropathy, but only ISS, International Staging System; PR, partial response. *Chi-square test for association. †Term 'polyneuropathy' includes the following related adverse events: hypoaesthesia oral, ageusia, aphasia, burning sensation, dysaesthesia, dysgeusia, hyperaesthesia, hypoaesthesia, hypogeusia, neuralgia, neuropathy, neuropathy peripheral, neurotoxicity, paraesthesia, peripheral sensory neuropathy, polyneuropathy, sensory disturbance, hypoaesthesia facial.
(A) (B)
Fig 2. Kaplan-Meier curves of progression-free survival and overall survival by the presence of cytogenetic abnormalities (high risk versus cytogenetic abnormalities with no negative predictive value versus no abnormalities) (N = 89): (A) Probability of progression-free survival. (B) Probability of overall survival. High-risk cytogenetic abnormalities were defined as deletion 17p, t(4;14) and gain 1q. Cytogenetic abnormalities with no negative predictive value included monosomies 4, 11, 13, 14 and 16; trisomies 3, 4, 5, 9, 11, 13, 15, 17 and 21; tetrasomies 5, 9, 11 and 15; deletions 11q, 13q, 14q and 22q; gains 9q and 17q; rearrangement/deletion at immunoglobulin heavy (IGH) locus; and translocations t(2;8) and t(11;14). For these chromosomal abnormalities, no prognostic information exists. P values represent results from log-rank tests versus high-risk cytogenetic abnormalities. CI, confidence interval; NE, not estimable; OS, overall survival; PFS, progression-free survival.
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ª 2017 John Wiley & Sons Ltd 3% had grade 3 polyneuropathy-related AEs (with no grade 4 events) and incidences of individual related AEs were no higher than those previously reported for VCD and other bortezomib-based regimens (Kropff et al, 2007 (Kropff et al, , 2009 Reeder et al, 2010; Ludwig et al, 2013) . Furthermore, these events resolved without sequelae in 75% of patients, with a mean time to resolution of 28Á6 days (median: 17Á5 days). The shorter time to resolution of polyneuropathy-related AEs compared with previous reports of bortezomib-based therapy ) may relate to the lack of intensive monitoring during the trial and/or the short duration of bortezomib treatment. As inflammation is a major contributor to bortezomib-related peripheral neuropathy, another possible explanation may lie in the anti-inflammatory effects of dexamethasone and in the immunosuppressive effects of cyclophosphamide that may have modified the course of neuropathy (Jaggi & Singh, 2012; Merz et al, 2016) . It should be noted that bortezomib was administered intravenously in this study. Since the initiation of this trial, subcutaneous bortezomib administration has been shown to be associated with comparable efficacy, increased convenience and an improved safety profile (Moreau et al, 2011b; Hoy, 2013) , with a lower rate of polyneuropathy compared with intravenous administration [all grades, 38% vs. 53% (P = 0Á044); grade ≥3 6% vs. 16% (P = 0Á026)]. This has resulted in widespread adoption of subcutaneous bortezomib. Bortezomib dose reductions and once-versus twice-weekly regimens have also been shown to decrease associated rates of polyneuropathy Minarik et al, 2015) , potentially as a consequence of patients receiving a lower cumulative dose.
The toxicity rates observed in this study (particularly haematological and neurological toxicities), as well as ORRs and VGPR rates, were similar to those reported in a recent case-matched control study comparing VTD and VCD across two large clinical trials wherein the VCD comparator was very similar to the one used here (the only difference being in the administration of cyclophosphamide: 900 mg/ m 2 on Day 1 in the present study versus 500 mg/m 2 on days 1 and 8 in the case-matched control study) (Cavo et al, 2015) . In the VTD/VCD comparison study, VTD was associated with lower rates of haematological toxicities but higher rates of peripheral neuropathy and rash, as well as an improved ORR, VGPR and CR when compared with VCD, after three cycles of induction therapy (Cavo et al, 2015) . In summary, the results of this study confirm the utility of VCD induction for previously untreated MM, including patients with poor-risk cytogenetic abnormalities. Furthermore, it is associated with an acceptable tolerability profile, including low mortality, low risk of infection and low incidence of severe and acceptable rates of mild/moderate treatment-emergent polyneuropathy, and is feasible in an outpatient setting. It is possible that subcutaneous bortezomib could even lower the rate of VCD-associated neuropathy. Based on these data, VCD induction has become a standard frontline treatment for transplant-eligible patients in all German myeloma centres. This approach is also consistent with current international clinical practice (Engelhardt et al, 2014) . and Dietrich Peest for their contributions to the development of this manuscript. The authors would like to acknowledge the writing assistance of Jane Saunders and Tamara Bailey of FireKite, an Ashfield company, part of UDG Healthcare plc, during the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc. and Janssen Global Services, LLC.
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